Third vaccine dose, new record: over 164 thousand in one day

New record for the third dose of the anti Covid vaccine. “Yesterday we made a new record of third doses, over 164 thousand, and therefore we hope that things will continue in this way” said the extraordinary commissioner for the coronavirus emergency, General Francesco Paolo Figliuolo, in connection with the Open day for women in pregnant and breastfeeding at the Sant’Eugenio hospital in Rome. Read also “To date we have almost 95 million doses, we have distributed over 100 million vaccines” added Figliuolo, explaining that “the reopening of the Cecchignola vaccination hub is near, precisely to increase third doses in Lazio and Rome. “. “In our team work, Lazio have really done their part very well” he underlined. From tomorrow Wednesday 24 November it will be possible to carry out the third dose of vaccine 5 months after the first cycle. This is what the circular of the Ministry of Health establishes. “Given the opinion of the CTS of Aifa, taking into account the current condition of increased viral circulation and resumption of the epidemic curve and with a view to maximum precaution, it is reported that, starting from the day following the publication in the Official Gazette of the relative determination by Aifa, as part of the anti-Sars-CoV-2 / Covid-19 vaccination campaign, the minimum interval foreseen for the administration of the “booster” dose (booster) with m-Rna vaccine, to the categories for which it is already recommended (including all subjects vaccinated with a single dose of Janssen vaccine) and in the dosages authorized for it (30 mcg in 0.3 mL for Pfizer / BioNTech Comirnaty; 50 mcg in 0.25 mL for Spikevax di Moderna), is updated to five months (150 days) from the completion of the primary vaccination cycle, regardless of the vaccine previously used “, reads the circular today in the Gazzetta.” Finally, we take this opportunity to reiterate what has already been about the possibility, within the same vaccination session, to co-administer an anti-Sars CoV-2 / Covid-19 m-RNA vaccine (both in the case of primary and booster cycles) and an influenza vaccine, in compliance with good vaccination practice “.